Expression of HIF-1α and Glut-1 in human bladder cancer

Victor Palit, R. M. Phillips, R. Puri, T. Shah, M. C. Bibby

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

HIF-1 is a heterodimer consisting of the HIF-1α and HIF-1β subunits, and HIF-1α is the unique oxygen regulated subunit that determines HIF-1 activity. HIF-1α upgrades many gene products which include the glucose transporter protein 1 (Glut-1). Immunohistochemical studies using a monoclonal antibody specific for HIF-1α indicate that the overexpression of HIF-1α occurs in the most common forms of human cancer, including bladder cancer. The expression of Glut-1 in human bladder cancer is associated with poor prognosis and a low survival rate. To our knowledge this is the first study to compare the expression of both HIF-1α and Glut-1 with clinico-pathological characteristics in superficial and invasive human bladder cancer (all invasive bladder cancer patients received radical radiotherapy). The Kaplan-Meier survival analysis curve shows a significant association of HIF-1α expression with recurrence and survival in superficial bladder cancer and shows a significant association of Glut-1 with survival in invasive bladder cancer [chi2 (4)=10.52; Pr > chi2=0.0012].

LanguageEnglish
Pages909-913
Number of pages5
JournalOncology Reports
Volume14
Issue number4
DOIs
Publication statusPublished - Oct 2005
Externally publishedYes

Fingerprint

Facilitative Glucose Transport Proteins
Urinary Bladder Neoplasms
Proteins
Kaplan-Meier Estimate
Survival
Survival Analysis
Radiotherapy
Survival Rate
Monoclonal Antibodies
Oxygen
Recurrence
Genes

Cite this

Palit, Victor ; Phillips, R. M. ; Puri, R. ; Shah, T. ; Bibby, M. C. / Expression of HIF-1α and Glut-1 in human bladder cancer. In: Oncology Reports. 2005 ; Vol. 14, No. 4. pp. 909-913.
@article{ceb36afae7ce4204a815203ee80e5a5d,
title = "Expression of HIF-1α and Glut-1 in human bladder cancer",
abstract = "HIF-1 is a heterodimer consisting of the HIF-1α and HIF-1β subunits, and HIF-1α is the unique oxygen regulated subunit that determines HIF-1 activity. HIF-1α upgrades many gene products which include the glucose transporter protein 1 (Glut-1). Immunohistochemical studies using a monoclonal antibody specific for HIF-1α indicate that the overexpression of HIF-1α occurs in the most common forms of human cancer, including bladder cancer. The expression of Glut-1 in human bladder cancer is associated with poor prognosis and a low survival rate. To our knowledge this is the first study to compare the expression of both HIF-1α and Glut-1 with clinico-pathological characteristics in superficial and invasive human bladder cancer (all invasive bladder cancer patients received radical radiotherapy). The Kaplan-Meier survival analysis curve shows a significant association of HIF-1α expression with recurrence and survival in superficial bladder cancer and shows a significant association of Glut-1 with survival in invasive bladder cancer [chi2 (4)=10.52; Pr > chi2=0.0012].",
keywords = "Bladder cancer, Glut-1, HIF-1α",
author = "Victor Palit and Phillips, {R. M.} and R. Puri and T. Shah and Bibby, {M. C.}",
year = "2005",
month = "10",
doi = "10.3892/or.14.4.909",
language = "English",
volume = "14",
pages = "909--913",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

Expression of HIF-1α and Glut-1 in human bladder cancer. / Palit, Victor; Phillips, R. M.; Puri, R.; Shah, T.; Bibby, M. C.

In: Oncology Reports, Vol. 14, No. 4, 10.2005, p. 909-913.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of HIF-1α and Glut-1 in human bladder cancer

AU - Palit, Victor

AU - Phillips, R. M.

AU - Puri, R.

AU - Shah, T.

AU - Bibby, M. C.

PY - 2005/10

Y1 - 2005/10

N2 - HIF-1 is a heterodimer consisting of the HIF-1α and HIF-1β subunits, and HIF-1α is the unique oxygen regulated subunit that determines HIF-1 activity. HIF-1α upgrades many gene products which include the glucose transporter protein 1 (Glut-1). Immunohistochemical studies using a monoclonal antibody specific for HIF-1α indicate that the overexpression of HIF-1α occurs in the most common forms of human cancer, including bladder cancer. The expression of Glut-1 in human bladder cancer is associated with poor prognosis and a low survival rate. To our knowledge this is the first study to compare the expression of both HIF-1α and Glut-1 with clinico-pathological characteristics in superficial and invasive human bladder cancer (all invasive bladder cancer patients received radical radiotherapy). The Kaplan-Meier survival analysis curve shows a significant association of HIF-1α expression with recurrence and survival in superficial bladder cancer and shows a significant association of Glut-1 with survival in invasive bladder cancer [chi2 (4)=10.52; Pr > chi2=0.0012].

AB - HIF-1 is a heterodimer consisting of the HIF-1α and HIF-1β subunits, and HIF-1α is the unique oxygen regulated subunit that determines HIF-1 activity. HIF-1α upgrades many gene products which include the glucose transporter protein 1 (Glut-1). Immunohistochemical studies using a monoclonal antibody specific for HIF-1α indicate that the overexpression of HIF-1α occurs in the most common forms of human cancer, including bladder cancer. The expression of Glut-1 in human bladder cancer is associated with poor prognosis and a low survival rate. To our knowledge this is the first study to compare the expression of both HIF-1α and Glut-1 with clinico-pathological characteristics in superficial and invasive human bladder cancer (all invasive bladder cancer patients received radical radiotherapy). The Kaplan-Meier survival analysis curve shows a significant association of HIF-1α expression with recurrence and survival in superficial bladder cancer and shows a significant association of Glut-1 with survival in invasive bladder cancer [chi2 (4)=10.52; Pr > chi2=0.0012].

KW - Bladder cancer

KW - Glut-1

KW - HIF-1α

UR - http://www.scopus.com/inward/record.url?scp=33644819081&partnerID=8YFLogxK

UR - https://www.spandidos-publications.com/or

U2 - 10.3892/or.14.4.909

DO - 10.3892/or.14.4.909

M3 - Article

VL - 14

SP - 909

EP - 913

JO - Oncology Reports

T2 - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -